
    
      Subjects in Part 1 will be randomized to receive LY2405319 or placebo over 7 days in one of 4
      dose level groups, in ascending order: 1 mg, 3 mg, 10 mg, or 20 mg.

      Subjects in Part 2 will be randomized to receive LY2405319 or placebo over 28 days, and will
      receive the dose level determined to be the most well tolerated in Part 1.
    
  